CB2029, another of Canopus’ radiation protection drug candidates, has proven effective at preventing radiation sickness and death in vivo, by protecting the GI tract from damage induced by high doses of radiation (e.g. oral mucositis).
Canopus has initiated an in dept analysis of the mechanisms involved in radiation injury to the lower GI tract, where CB2029 will be examined to confirm its effectiveness as an anti-enteritis and anti-proctitis agent.
Canopus currently has international patents pending relating to the use of CB2029 as a radioprotective agent. This application has been entered into the national phase.